Merck takeover $1.75 a share, page-42

Merck and BristolMS are competing in the same lucrative space.

CAVATAK has been proven to make both more effective and much safer.

Now if this deal goes through, not only has BristolMS lost the chance for a better and safer product, but their competior's drug has become better and safer.

I think BristolMS have to counter this, or they lose heaps in sales.

So personally I suggest you keep hold of those vla shares.

One shark has had a nibble. There's now blood in the water and the other sharks will smell it!